Quanta Announces Dosing of First Patient in Phase 1/1b Clinical Trial of QTX3046, an Oral KRASᴳ¹²ᴰ-Selective Dual-State Allosteric Inhibitor, and Other Program Updates
June 27, 2024 09:00 ET
|
Quanta Therapeutics, Inc.
Quanta is advancing 2 clinical trials from its pipeline of KRAS G12D-focused drug candidates, as monotherapy and combination with EGFR inhibitors
Quanta Presents Preclinical Data for QTX3544, a Potent and Selective G12V-preferring Multi-KRAS Inhibitor, in Late-Breaking Session at Annual AACR Meeting 2024
April 08, 2024 09:00 ET
|
Quanta Therapeutics, Inc.
–Strong anti-tumor activity, favorable oral bioavailability and drug-like properties demonstrated in preclinical models – –Data support ongoing IND-enabling studies for planned clinical...
Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, a G12V-preferring multi-KRAS inhibitor, at AACR Annual Meeting
March 05, 2024 16:31 ET
|
Quanta Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering targeted therapies to treat RAS-driven cancers, today...
Quanta Announces IND Clearance by U.S. FDA for QTX3034, G12D-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
January 04, 2024 08:00 ET
|
Quanta Therapeutics, Inc.
QTX3034, G12D-preferring multi-KRAS inhibitor, IND received clearance by US FDA to begin Phase 1 study; planned for 1Q24; and other pipeline updates
Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference
October 11, 2023 12:00 ET
|
Quanta Therapeutics, Inc.
The combination of QTX3034, a multi-KRAS inhibitor, and EGFR inhibitors demonstrated potent, synergistic anti-tumor activity in preclinical studies.
Quanta Therapeutics Raises Over $50 Million in Series D Financing to Advance its Pipeline of KRAS Inhibitors
May 22, 2023 09:00 ET
|
Quanta Therapeutics, Inc.
– Funds will support advancement of two KRAS inhibitor programs into the clinic in 2024 –– Financing led by Avidity Partners, with participation from syndicate of existing investors – RADNOR, Pa....
Quanta Therapeutics Presents Data from KRAS Inhibitor Pipeline at Annual AACR Meeting in Late-Breaking Research Session
April 14, 2023 12:05 ET
|
Quanta Therapeutics, Inc.
- Data highlight favorable preclinical profiles for two chemically-distinct allosteric, oral small molecule KRAS inhibitors with potent anti-tumor activity - ORLANDO, Fla., April 14, 2023 (GLOBE...
Quanta Therapeutics Announces Two Late-Breaking Preclinical Presentations from KRAS Inhibitor Pipeline at Annual AACR Meeting
March 14, 2023 16:35 ET
|
Quanta Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held biopharmaceutical company pioneering complex-directed therapies to treat RAS-driven cancers,...
Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical Officer
December 13, 2022 08:55 ET
|
Quanta Therapeutics, Inc.
– US board-certified medical oncologist with extensive global clinical and regulatory experience advancing oncology medicines from early development stages through to approval – – Quanta is...